Sinds februari 1999 heeft dr. Bihari nu 242 patiënten behandeld met naltrexone.  Ik moet er wel bij opmerken dat Dr. Bihari  natuurlijk alle belang heeft bij goede resultaten. Maar tegelijkertijd komt de informatie over als betrouwbaar, kritisch en eerlijk. Zo wordt ook gemeld dat maar liefst van 98 patiënten geen vervolggegevens beschikbaar zijn, omdat die na de behandeling gewoon geen contact meer hebben opgenomen met Dr. Bihari. Ik vind dat wel erg veel moet ik zeggen. Maar de waarde van dit alles kan ik natuurlijk niet beoordelen. Wel valt me op dat er van de overgebleven 144 patiënten er 44 zijn overleden, bijna allemaal binnen zes tot acht weken na het starten van de behandeling, dus lijkt het dat veel echt terminale patiënten hieraan zijn begonnen. Verdere resultaten: van de 102 overgebleven patiënten gebruiken er 44 naltrexone meer dan zes maanden nu en bij 21 worden remissies gemeten van totale remissie tot meer dan 75% remissie.  De anderen (23) hebben wel remissie, maar halen de 75% norm nog niet. Van de 56 patiënten die stopten na een tijdje met naltrexone krgen er 9 een zikteprogressie, maar bij 49 bleef de ziekte stabiel of slonk zelfs de tumormassa. 

Een opmerking die opvalt is dat prostaatkankerpatiënten die PC-Spes hebben gebruikt of gebruiken niet reageren op de naltrexone in tegenstelling tot andere prostaatkankerpatiënten die er wel op reageren. Maar zo beschrijft Dr. Bihari het.

Recent Developments
Since February 1999, Dr. Bihari has begun treatment of 242 cancer patients with LDN (see chart below). Since many of these patients, particularly those seen before October 2000, were seen only once in consultation with medical follow-up by their oncologists, he is missing up-to-date follow-up data on 96 patients.

As of March 2001, of the remaining 146 patients, 44 have died, all but 4 of cancer-related causes. Most of these deaths have occurred in the first 8 to 12 weeks on LDN. For the most part, these were patients who were quite ill when first seen, and had exhausted all other treatment possibilities. Of the remaining 102 patients, 44 have been on LDN for six months or longer. Of these, 21 have shown significant movement toward remission, identified for this purpose as a reduction of at least 75% in tumor mass and tumor-related symptoms. The other 23 patients have stabilized and/or are moving toward remission but do not yet meet the 75% reduction criterion.

Of the 58 patients not on LDN for six months as yet, 9 continue to show disease progression and 49 have stabilized with no disease progression and/or reduction of less than 75% in tumor bulk.


Among the 21 who have shown significant movement toward remission, 6 had never received chemotherapy. Another 9 stopped chemotherapy during the first 3 to 4 months on LDN, and the remaining 6 are still receiving chemotherapy. The apparent remissions include:

2 children with neuroblastoma 
3 patients with non-Hodgkin's lymphoma 
2 with Hodgkin's disease 
2 with pancreatic cancer 
3 with multiple myeloma 
1 with carcinoid 
1 with breast cancer metastatic to bone 
4 with ovarian cancer 
1 with small cell cancer of the lung 
2 with prostate cancer (no prior hormone-blocker therapy)

(Although recently-diagnosed prostate cancer patients who have not received other therapies appear to do well on LDN, patients with prostate cancer who have already been treated with hormone-related therapies, including testosterone-blocking drugs and PC-Spes, have not responded to LDN.) 
An overview of these results must assume on basic statistical principle that the patients with no follow-up contact have not done as well as those who have maintained continual medical contact with Dr. Bihari. Measured in terms of disease stabilization and/or movement toward remission, and assuming that patients in continual follow-up are twice as likely to have had a good outcome thus far, it appears that one-quarter to one-third of all cancer patients who Dr. Bihari has started on LDN have done well.

Taking into account the relatively large number of patients who were in advanced stages of disease when first seen by Dr. Bihari, it appears that somewhere between 30% and 50% of patients with cancer may benefit from LDN. It will clearly require extensive study of LDN in prospective, controlled clinical trials to determine which cancers respond best and which other therapies are complementary or synergistic with LDN


Plaats een reactie ...

Reageer op "Beschrijving van 242 patienten die naltrexone kregen als aanvullende behandeling."


Gerelateerde artikelen